CC
ACAD icon

Callan Capital’s Acadia Pharmaceuticals ACAD Stock Holding History

Callan Capital’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-5,000
Closed -$209K – 63
2015
Q2 		$209K Sell
5,000
-5,000
-50% -$194K 0.04% 64
2015
Q1 		$326K Hold
10,000
– – 0.07% 56
2014
Q4 		$318K Hold
10,000
– – 0.07% 61
2014
Q3 		$248K Buy
+10,000
New +$234K 0.07% 60

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Callan Capital's ACAD Position: Q3 2015 in Review

Callan Capital sold out of Acadia Pharmaceuticals (ACAD) in Q3 2015, closing a stake of 5,000 shares — an estimated $209K sold.

Callan Capital first reported a position in ACAD in Q3 2014 and held it in 4 quarters. The position peaked at $326K in Q1 2015. 188 funds tracked by Wall St. Rank hold ACAD as of Q3 2015.

  • Callan Capital reported no remaining Acadia Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Callan Capital sold 5,000 Acadia Pharmaceuticals shares in Q3 2015, an estimated $209K.
  • Callan Capital first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 4 quarters.
  • Callan Capital's Acadia Pharmaceuticals position peaked at $326K in Q1 2015.
  • 188 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q3 2015.

Based on Callan Capital's 13F filing for Q3 2015, filed 10 Nov 2015.